Fibroblast growth factor-23 (FGF-23) is a bone-derived hormone that participates in a bone--kidney endocrine network regulating mineral metabolism. FGF-23 is produced by osteoblasts and osteocytes in bone and enters the circulation to inhibit phosphate reabsorption and reduce serum 1,25D levels through the activation of canonical FGFR/α-Klotho receptor complexes in renal tubules ([@B1]--[@B3]). The major physiological functions of FGF-23 are to (1) coordinate bone mineralization with renal handling of phosphate ([@B1], [@B4]) and (2) act as a counter-regulatory hormone for 1,25D (Figure [1](#F1){ref-type="fig"}A). Elevated levels of FGF-23 are associated with several hereditary and acquired hypophosphatemic disorders including X-linked hypophosphatemic rickets (Hyp mice homolog)---caused by inactivating mutations of *Phex* ([@B5]--[@B7])---autosomal recessive hypophosphatemic rickets 1---caused by inactivating mutations of *Dmp1* ([@B5], [@B7])---ARHR2---caused by inactivating mutations in *Enpp1* ([@B6]--[@B10])---and Raine syndrome---caused by inactivating mutations in FAM20C ([@B11], [@B12]). Increased FGF-23 is the result of either increased gene transcription or diminished cleavage of FGF-23 in these disorders.

![Mechanisms of fibroblast growth factor-23 (FGF-23) effects to impair innate immune responses. **(A)** FGF-23 bone--kidney--cardiac--immune axis. FGF-23 is produced by osteoblasts/osteocytes in bone in response to local and systemic factors and targets the kidney to create multiple endocrine networks ([@B4], [@B13]) in bone, including (1) an FGF-23 vitamin D counter-regulatory loop ([@B4], [@B14]); (2) a calcium-FGF-23 endocrine loop, where calcium stimulates FGF-23 in bone and FGF-23 stimulates calcium reabsorption in the DT ([@B15], [@B16]); (3) a bone--kidney axis, where FGF-23 is regulated by factors involved in extracellular matrix mineralization to coordinate renal phosphate handling ([@B1]). In addition, there is a bone--renal--cardiac axis that augments hemodynamic responses through a feed forward bone--cardio--renal loop, where angiotensin II (Ang II) stimulates FGF-23 production in bone ([@B17]) and FGF-23 suppresses Ace2 in the kidney ([@B18]), a volume regulatory loop where diuretics and aldosterone stimulate FGF-23 production by bone and FGF-23 targets the distal tubule to increase sodium reabsorption, and a FGF-23 soluble Klotho (sKl) regulatory axis, where FGF-23 suppresses α-Kl expression in the distal tubule leading to reduction in sKl and loss of the hormonal effects of this antiaging hormone. In this schema, FGF-23 regulates innate immune response through suppression of 1,25(OH)D2 production by the kidney. **(B)** Paracrine effects of FGF-23 on innate immune responses. Macrophages do not normally express FGF-23 or α-Klotho, but in the setting of infection, LPS/IFNγ induces the ectopic expression of both FGF-23 and its co-receptor α-Klotho that reconstitutes paracrine FGF-23 signaling in macrophages. FGF-23 stimulates pro-inflammatory responses in M1 macrophages and blocks the transition to M2 macrophages ([@B3]). In addition, FGF-23 is proposed to directly activate FGFR2 in PMNs to decrease recruitment ([@B19]).](fendo-09-00320-g001){#F1}

Role of FGF-23 in Inflammation {#S1}
==============================

There are emerging data that FGF-23 may have effects on immune responses. Vitamin D, which is regulated by FGF-23, has well-described effects on both innate and adaptive immunity ([@B20]--[@B22]). Vitamin D has an overall effect to enhance innate immune responses and exert anti-inflammatory effects through local and systemic effects. Evidence that FGF-23 may have an overall impact on immunity comes from the association between elevated FGF-23 levels and inflammation. FGF-23 is increased in inflammatory bowel disease ([@B23]) and chronic kidney disease (CKD) ([@B4]). In CKD, elevated FGF-23 initially functions to maintain mineral homeostasis, but persistent elevations are maladaptive and associated with increased morbidity and mortality ([@B24]--[@B26]), cardiovascular disease ([@B26]--[@B30]), inflammation, and infections ([@B31], [@B32]). Infections, most commonly caused by infected catheters and pneumonia ([@B33]), are second to cardiovascular disease in causing death in CKD ([@B34]) and are \>100-fold higher than the general population. Recent clinical association studies suggest that elevated FGF-23 contributes to an increase in susceptibility or severity of infections in CKD. Moreover, elevated FGF-23 levels correlated with increased IL-6, TNFα, CRP, fibrinogen, and severe inflammation in CKD patients ([@B31], [@B35]). In a CKD mouse model of bacterial pneumonia, FGF-23 administration exacerbated disease severity and its inhibition improved outcomes ([@B19]). Although these studies suggest that FGF-23 interacts with the immune system, they do not reveal whether FGF-23 directly regulates immune cell functions or indirectly affects immune responses through FGF-23 regulation of 1,25D.

Inflammatory Stimuli Induce FGF-23 Expression in Osteoblasts/Osteocytes and Immune Cells {#S2}
========================================================================================

Inflammatory stimuli upregulate FGF-23 expression in bone, where FGF-23 is usually expressed, but also in immune cells and tissues that do not normally express FGF-23. Inflammatory cytokines have been shown to induce FGF-23 expression *in vivo* and *in vitro*. Inflammation increases circulating FGF-23 levels in both animal models and humans in response to infection, inflammation, and oxidative stress ([@B36]--[@B38]). For example, mouse serum FGF-23 levels are significantly increased following inoculation with Gram-negative (*E. coli*) or Gram-positive (*S. aureus*) bacteria, or LPS administration in mice ([@B37]). Numerous studies have demonstrated that FGF-23 transcription in osteoblasts/osteocytes is regulated by LPS, IL-1β, and TNFα ([@B39]). An enhancer residing in the −16 kb region of FGF-23 was identified and following deletion using CRISPR/Cas9 technology was demonstrated to be responsible for the stimulation of FGF-23 transcription by inflammatory stimuli ([@B40]). Bacterial components stimulate immune cells through toll-like receptors (TLRs) and stimulation of TLRs 2, and 4 on bone marrow-derived dendritic cells increased FGF-23 mRNA expression. TLR4 recognizes the bacterial cell wall component LPS, and TLR2 recognizes lipotechoic acids present in bacterial membranes leading to the activation of NF-κB pathway. Inhibition of NF-κB activation prevented the upregulation of FGF-23 mRNA in response to LPS stimulation. Hif1α is another transcription factor that stimulates FGF-23 in osteoblasts ([@B41]), indicating that oxidative stress/inflammation stress may induce expression of FGF-23.

Macrophages may be central to FGF-23 regulation and function. Resting RAW264.7 macrophages, which do not normally express FGF-23, when stimulated with LPS/IFN-γ to induce M1 polarization express significant increases in FGF-23. The increase is also mediated by NF-κB-dependent activation of the FGF-23 promoter ([@B3]). In addition, the M1 macrophages upregulate Klotho transcription, including the full-length α-Kl message and the alternatively spliced s-Kl message and protein levels. By contrast, IL-4 induction of M2 macrophages results in only modest increases in FGF-23 expression and no upregulation of α-Klotho transcription. Not only do macrophages make FGF-23 and respond to FGF-23 (see below), but make other cytokines, such as OSM, that induce tissue expression of FGF-23, such as in cardiomyocytes ([@B42]). In contrast to M1 macrophages, Masuda et al. ([@B37]) did not observe upregulation of FGF-23 mRNA in T cells stimulated with the polyclonal stimulators PMA and ionomycin. Lymphocytes also express TLRs 2 and 4, and it is not known whether stimulation through these receptors will upregulate FGF-23 mRNA in these cells.

These observations suggest that inflammatory mediators stimulate FGF-23 gene transcription in osteoblasts/osteocytes that normally express FGF-23 and in macrophages and tissues that do not normally express FGF-23. The resulting local and systemic production of FGF-23 may play a critical role in the ensuing immune responses through targeting FGFR/α-Klotho receptor complexes in the kidney or reconstituted receptor complexes in the local inflammatory tissue environment.

Potential Mechanisms for FGF-23 Impairment of Host Responses {#S3}
============================================================

Indirect Effects Mediated by FGF-23 Suppression of 1,25D {#S3-1}
--------------------------------------------------------

Under physiological conditions, changes in FGF-23 results in reciprocal changes in 1,25D, and *vice versa*. FGF-23 may affect immune responses through activation of FGFR/α-Klotho complexes in the proximal renal tubule leading to suppression of 1,25D by the kidney ([@B3], [@B19], [@B43]--[@B46]). The association between low vitamin D and high FGF-23 serum levels with infectious and cardiac deaths in a large cohort of patients with end-stage renal disease ([@B47], [@B48]) may be due to the loss of the anti-inflammatory effects of 1,25D ([@B49], [@B50]). The loss of 1,25D may result in the amplification of inflammatory response and subsequently increased tissue pathology.

Direct Effects of FGF-23 on Macrophages and PMNs {#S3-2}
------------------------------------------------

Another mechanism is direct pro-inflammatory actions of FGF-23 on immune cells. There is emerging evidence that FGF-23 directly interacts with immune cells, such as PMNs and/or macrophages through binding of FGFR/α-Kl receptors (Figure [1](#F1){ref-type="fig"}B).

Rossaint et al. ([@B19]) used a murine model of CKD, induced by 5/6 nephrectomy, to measure the effect of excess FGF23 on *E. coli* pneumonia. The authors demonstrate that mice with CKD had decreased recruitment of PMNs into the lungs and increased disease severity. Neutralization of FGF23 with anti-FGF23 antibody restored PMN recruitment and the host response in these mice. The authors proposed that elevated circulating levels of FGF-23 directly activated FGFR2 in PMNs to impair the host response to infection.

Direct effects of FGF-23 on PMNs are controversial for several reasons. First, PMNs lack the obligate FGF-23 co-receptor α-Klotho. To deal with this inconsistency, this hypothesis proposes that FGF-23 targets PMNs through the non-canonical FGFR2 pathway ([@B2]). Second, FGFR2, which is the only FGFR expressed in PMNs, is not a target for FGF-23 in multiple functional studies and target engagement assays ([@B2], [@B51]--[@B53]). Third, experimental designs in existing studies are not sufficient to establish the role of FGFR2 or PMNs in mediating FGF-23's adverse effects on host responses. In this regard, a single intravenous injection of 200 ng of rFGF-23 to mice was the only *in vivo* evidence that elevated FGF-23 impairs PMN responses to sepsis. Essential studies to ablate FGFR2 in PMNs or to test the effects of chronic elevations of FGF-23 in the absence of confounding effects of CKD ([@B19], [@B54]) have not been performed. Finally, effects of FGF-23 inhibition to improve outcomes with a blocking antibody have not controlled for confounding effects of reciprocal increases in 1,25D production in response to FGF-23 inhibition.

There is compelling data that FGF-23 targets macrophages. Several studies have demonstrated that macrophages and DCs express FGFR1 and inflammatory stimuli upregulates α-Klotho expression in macrophages to reconstitute FGFR--α-Klotho signaling ([@B3], [@B37]). Stimulation of these cells with FGF-23 resulted in induction of TNF-α mRNA and protein expression in primary macrophages as well as macrophage cell lines through activation of binary FGFR/α-Klotho complexes ([@B3], [@B37]). In addition, the ability of FGFR inhibitors to block FGF-23 signaling in macrophages confirms that the canonical FGFR/Kl signaling pathway is active in macrophages ([@B3]).

If FGF-23 is directly affecting innate immune responses, animal models with elevated FGF-23 should exhibit abnormal host responses even in the absence of CKD. Indeed, a sterile inflammation model to induce the infiltration of peritoneal macrophages with thioglycolate shows that Hyp mice have increased FGF-23 expression in macrophages ([@B3]). Macrophages isolated from Hyp mice expressed higher levels of FGF-23 and Klotho compared with WT controls. Hyp macrophages also had increased basal ERK activation and increased TNF-α mRNA, consistent with activation of FGFR/αKl signaling. Serum levels of TNF-α were increased consistent with the pro-inflammatory phenotype \[i.e., kidney inflammation ([@B18]) and cardiovascular abnormalities in Hyp mice ([@B55])\]. These data support the hypothesis that locally produced and circulating FGF-23 activate immune cells in the inflammatory milieu ([@B3], [@B43]), leading to adverse outcomes ([@B56]). In this scenario, infection with bacteria stimulates the production of FGF-23 locally in M1 activated macrophages which also upregulate FGFR/α-Kl complexes ([@B3]). Autocrine stimulation of the M1 cells with FGF23 amplifies TNF production and inhibits the transition to a wound healing M2 phenotype, resulting in excess tissue damage and increased morbidity and mortality (Figure [1](#F1){ref-type="fig"}B).

Based on these findings, a new hypothesis proposes that FGF-23 actions on innate immunity are mediated by activation of reconstituted canonical FGFR/α-Kl receptors in tissue macrophages during infections by both systemic and local production of FGF-23 (Figure [1](#F1){ref-type="fig"}B) ([@B3], [@B19], [@B37], [@B43]). Although the full effects of FGF-23 on immune cell function remain to be defined, in this schema, FGF-23 is proposed to have pro-inflammatory effects mediated by activated macrophages. Additional studies are needed to characterize the impact of FGF-23 on immune responses. In particular, experiments that conditional delete FGF-23, FGFRs, and α-Klotho in different myeloid cells are needed to define the role of FGF-23/FGFR/α-Klotho signaling in mediating immune responses.

Role of α-Klotho and Soluble Klotho (sKl) in Inflammation {#S4}
=========================================================

α-Klotho gene has two transcripts that encode a long type I transmembrane (TM) protein containing KL1 and KL2 domains and a short secreted protein containing only a single KL domain ([@B57]). The \~130-kDa TM protein is an obligate co-receptor for binding of FGF-23 to FGFRs ([@B2], [@B58]). Ectodomain shedding by ADAM10 and ADAM17 generates a circulating α-Klotho isoform that lacks the TM domain ([@B59]). The short secreted \~60-kDa isoform (s-KL) is generated by the alternative spliced transcript. Similar sized as soluble KL1 and KL2 fragments are also generated by additional post-translational cleavage of the shed isoform ([@B57], [@B60]). The \~60-kDa s-KL gene product emerged during evolution before FGF-23 and likely has FGF-23 independent functions, including antiaging, anti-inflammatory, and anti-fibrotic effects due to actions of secreted forms of KL to inhibit Wnt, IGF-1, and TGF-β signaling ([@B61]--[@B65]). Since excess FGF-23 is associated with decreased expression of α-Klotho in the kidney and circulating Kl, it is difficult to determine if the adverse effects attributed to excess FGF-23 are actually caused by Klotho deficiency. Indeed, Klotho depletion is associated with increased inflammation in multiple experimental models.

A recent study showed that renal Klotho mRNA and protein were significantly decreased leading to increased inflammation in kidney of the *db/db* mouse model of diabetes ([@B66]). Addition of sKl or overexpression of α-Klotho suppressed NF-κB activation and subsequent production of inflammatory cytokines in response to TNF-α stimulation *in vitro*. Klotho serves as an anti-inflammatory modulator, which negatively regulates the production of NF-κB-linked inflammatory proteins *via* a mechanism that involves phosphorylation of Ser^536^ in the transactivation domain of RelA ([@B66]). Thus, distinguishing between FGF-23 and α-Klotho-dependent effects are important, because Klotho administration would correct abnormalities caused by FGF-23 suppression of Klotho.

FGF-23 Regulates Hemodynamic Responses to Counter the Hypotensive Effects of Inflammation {#S5}
=========================================================================================

Could FGF-23 effects regulate renal process that have cardiovascular effects, be linked to inflammatory responses ([@B53], [@B67])? For example, FGF-23 upregulates NCC in the DT leading to hypertension and suppression of aldosterone levels ([@B15], [@B16], [@B55]). FGF-23 administration suppresses ACE2 and αKl expression in the kidney, which could potentially cause left ventricular hypertrophy by enhancing the response to Ang II and/or decreasing circulating sKl ([@B68]). From a teleological perspective, FGF-23 control of blood pressure may serve to attenuate the hypotensive effects of inflammation, or alternatively account for the link between inflammation and hypertension ([@B69]).

Therapeutic Potential of FGF-23 Antagonist {#S6}
==========================================

If elevations of FGF-23 are causally linked to adverse outcomes, as emerging data are suggesting, then efforts to inhibit the end-organ effects of excess FGF-23 may improve outcomes in clinical conditions of FGF-23 excess. Advancements in pharmacological tools to block FGF-23 have been made, including blocking antibodies, which show efficacy and safety in treating hypophosphatemic rickets in hereditary disorders of FGF-23 excess ([@B70]). Blocking antibodies, however, have a narrow safety window and long half-life ([@B16], [@B70]), which may limit their use in CKD. Indeed, FGF-23-blocking antibody has not been shown to safely reduce FGF-23 in CKD without worsening hyperphosphatemia. Use of an FGF-23-blocking antibody also induced aortic calcification associated with increased risk of mortality in a rodent model of CKD ([@B16]). A novel FGF-23 antagonist, Zinc13407541, has been developed, which is short-acting and effectively antagonizes FGF-23 actions *in vitro* and *in vivo* without elevating serum phosphate ([@B71]). Unlike FGF-23-blocking antibodies, this small molecule compound can specifically block FGF-23/FGFR/Klotho signaling and increase serum 1,25(OH)~2~D levels ([@B71]) and suppresses TNF-α expression in activated macrophages. With further lead optimization, derivatives of Zinc13407541 could potentially be a titratable pharmacological tool to block FGF-23-related mortality in CKD.

In conclusion, a new understanding of FGF-23 functions proposes functions beyond mineral metabolism that includes indirect and direct effects on components of the myeloid lineage that may account for the association between elevated FGF-23 and impaired host responses to infections. Distinguishing between the proposed mechanisms, namely, FGF-23 suppression of 1,25D, activation of FGFR2 in PMNs in the absence of α-Klotho, and FGF-23 activation of canonical FGFR/α-Kl signaling in macrophages, is important, if we are to make progress in preventing and treating complications of excess FGF-23. Additional studies are needed to determine the relative importance of FGF-23 direct effect on different components of the myeloid lineage in regulating innate immune function and the clinical significance of FGF-23 actions to counteract the systemic and local immune effects of Vitamin D. Distinguishing between these direct and indirect effects will help establish whether pharmacological inhibition of FGF-23 or administration of 1,25D or sKl can prevent the adverse outcomes associated with FGF-23 excess.
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